REFERENCES
- Ando M., Ando Y., Sekido Y., Ando M., Shimokata K., Hasegawa Y. Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients. Jpn. J. Cancer Res 2002; 93(5)591–597, [INFOTRIEVE], [CSA]
- Ando Y., Hasegawa Y. Clinical pharmacogenetics of irinotecan (CPT-11). Drug Metab. Rev 2005; 37(3)565–574, [INFOTRIEVE], [CSA], [CROSSREF]
- Ando Y., Saka H., Ando M., Sawa T., Muro K., Ueoka H., et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60(24)6921–6926, [INFOTRIEVE], [CSA]
- Aono S., Yamada Y., Keino H., Hanada N., Nakagawa T., Sasaoka Y., et al. Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler-Najjar syndrome type II. Biochem. Biophys. Res. Commun 1993; 197(3)1239–1244, [INFOTRIEVE], [CSA], [CROSSREF]
- Beutler E., Gelbart T., Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?. Proc. Natl. Acad. Sci. U S A 1998; 95(14)8170–8174, [INFOTRIEVE], [CSA], [CROSSREF]
- Bosma P. J., Chowdhury J. R., Bakker C., Gantla S., de Boer A., Oostra B. A., et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med 1995; 333(18)1171–1175, [INFOTRIEVE], [CSA], [CROSSREF]
- Burchell B. Genetic variation of human UDP-glucuronosyltransferase. Implications in disease and drug glucuronidation. Am. J. Pharmacogenomics 2003; 3: 37–52, [INFOTRIEVE], [CSA], [CROSSREF]
- Burchell B., Blanckaert N. Bilirubin mono- and di-glucuronide formation by purified rat liver microsomal bilirubin UDP-glucuronyltransferase. Biochem. J 1984; 223(2)461–465, [INFOTRIEVE], [CSA]
- Burchell B., Brierley C. H., Rance D. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci 1995; 57(20)1819–1831, [INFOTRIEVE], [CSA], [CROSSREF]
- Burchell B., Coughtrie M. W. H. UD`P-glucuronosyltransferases. Pharmacol. Ther 1989; 43: 261–289, [INFOTRIEVE], [CSA], [CROSSREF]
- Butler L. M., Duguay Y., Millikan R. C., Sinha R., Gagne J. F., Sandler R. S., et al. Joint effects between UDP-glucuronosyltransferase 1A7 genotype and dietary carcinogen exposure on risk of colon cancer. Cancer Epidemiol. Biomarkers Prev 2005; 14(7)1626–1632, [INFOTRIEVE], [CSA], [CROSSREF]
- Carlini L. E., Meropol N. J., Bever J., Andria M. L., Hill T., Gold P., et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin. Cancer Res 2005; 11(3)1226–1236, [INFOTRIEVE], [CSA]
- Cersosimo R. J. Irinotecan: a new antineoplastic agent for the management of colorectal cancer. Ann. Pharmacother 1998; 32(12)1324–1333, [INFOTRIEVE], [CSA], [CROSSREF]
- Chabot G. G. Clinical pharmacokinetics of irinotecan. Clin. Pharmacokinet 1997; 33(4)245–259, [INFOTRIEVE], [CSA]
- Chowbay B., Sharma A., Zhou Q. Y., Cheung Y. B., Lee E. J. The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents. Oncol. Rep 2003; 10(3)745–751, [INFOTRIEVE], [CSA]
- Ciotti M., Marrone A., Potter C., Owens I. S. Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics 1997; 7(6)485–495, [INFOTRIEVE], [CSA]
- Ciotti M., Owens I. S. Evidence for overlapping active sites for 17 alpha-ethynlestradiol and bilirubin in the human major bilirubin UDPglucuronosyltransferase. Biochemistry 1996; 35(31)10119–10124, [INFOTRIEVE], [CSA], [CROSSREF]
- Clarke D. J., Cassidy A. J., See C. G., Povey S., Burchell B. Cloning of the human UGT1 gene complex in yeast artificial chromosomes: novel aspects of gene structure and subchromosomal mapping to 2q37. Biochem. Soc. Trans 1997; 25(4)S562, [INFOTRIEVE], [CSA]
- Cummings J., Boyd G., Macpherson J. S., Wolf H., Smith G., Smyth J. F., et al. Factors influencing the cellular accumulation of SN-38 and camptothecin. Cancer Chemother. Pharmacol 2002; 49(3)194–200, [INFOTRIEVE], [CSA], [CROSSREF]
- de Jong F. A., Marsh S., Mathijssen R. H., King C., Verweij J., Sparreboom A., et al. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin. Cancer Res 2004; 10(17)5889–5894, [INFOTRIEVE], [CSA], [CROSSREF]
- Desai A. A., Innocenti F., Ratain M. J. UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics 2003; 13(8)517–523, [INFOTRIEVE], [CSA], [CROSSREF]
- Dodds H. M., Tobin P. J., Stewart C. F., Cheshire P., Hanna S., Houghton P., et al. The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model. J. Pharmacol. Exp. Ther 2002; 303(2)649–655, [INFOTRIEVE], [CSA], [CROSSREF]
- Elahi A., Bendaly J., Zheng Z., Muscat J. E., Richie J. P., Jr., Schantz S. P., et al. Detection of UGT1A10 polymorphisms and their association with orolaryngeal carcinoma risk. Cancer 2003; 98(4)872–880, [INFOTRIEVE], [CSA], [CROSSREF]
- Fittkau M., Voigt W., Holzhausen H. J., Schmoll H. J. Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats. J. Cancer Res. Clin. Oncol 2004; 130(7)388–394, [INFOTRIEVE], [CSA], [CROSSREF]
- Gagne J. F., Montminy V., Belanger P., Journault K., Gaucher G., Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol. Pharmacol 2002; 62(3)608–617, [INFOTRIEVE], [CSA], [CROSSREF]
- Garcia-Carbonero R., Supko J. G. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res 2002; 8(3)641–661, [INFOTRIEVE], [CSA]
- Girard H., Court M. H., Bernard O., Fortier L. C., Villeneuve L., Hao Q., et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 2004; 14(8)501–515, [INFOTRIEVE], [CSA], [CROSSREF]
- Gong Q. H., Cho J. W., Huang T., Potter C., Gholami N., Basu N. K., et al. Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 2001; 11(4)357–368, [INFOTRIEVE], [CSA], [CROSSREF]
- Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 2003; 3(3)136–158, [INFOTRIEVE], [CSA], [CROSSREF]
- Guillemette C., Ritter J. K., Auyeung D. J., Kessler F. K., Housman D. E. Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 2000; 10(7)629–644, [INFOTRIEVE], [CSA], [CROSSREF]
- Hanioka N., Ozawa S., Jinno H., Ando M., Saito Y., Sawada J. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica 2001; 31(10)687–699, [INFOTRIEVE], [CSA], [CROSSREF]
- Ikegami T., Ha L., Arimori K., Latham P., Kobayashi K., Ceryak S., et al. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. Cancer Res 2002; 62(1)179–187, [INFOTRIEVE], [CSA]
- Innocenti F., Liu W., Chen P., Desai A. A., Das S., Ratain M. J. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics 2005; 15(5)295–301, [INFOTRIEVE], [CSA]
- Innocenti F., Undevia S. D., Iyer L., Chen P. X., Das S., Kocherginsky M., et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol 2004; 22(8)1382–1388, [INFOTRIEVE], [CSA], [CROSSREF]
- Ishikawa K., Kajita Y., Hasegawa Y., Noda Y., Yoshida J., Nabeshima T. Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity: case report. J. Neurooncol 2005; 74(3)283–286, [INFOTRIEVE], [CSA], [CROSSREF]
- Iyer L., Das S., Janisch L., Wen M., Ramirez J., Karrison T., et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2(1)43–47, [INFOTRIEVE], [CSA], [CROSSREF]
- Jinno H., Saeki M., Saito Y., Tanaka-Kagawa T., Hanioka N., Sai K., et al. Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients. J. Pharmacol. Exp. Ther 2003; 306(2)688–693, [INFOTRIEVE], [CSA], [CROSSREF]
- Jinno H., Saeki M., Tanaka-Kagawa T., Hanioka N., Saito Y., Ozawa S., et al. Functional characterization of wild-type and variant (T202I and M59I) human UDP-glucuronosyltransferase 1A10. Drug Metab. Dispos 2003; 31(5)528–532, [INFOTRIEVE], [CSA], [CROSSREF]
- Jinno H., Tanaka-Kagawa T., Hanioka N., Saeki M., Ishida S., Nishimura T., et al. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab. Dispos 2003; 31(1)108–113, [INFOTRIEVE], [CSA], [CROSSREF]
- Kehrer D. F., Sparreboom A., Verweij J., de Bruijn P., Nierop C. A., van de Schraaf J., et al. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin. Cancer Res 2001; 7(5)1136–1141, [INFOTRIEVE], [CSA]
- Kitagawa C., Ando M., Ando Y., Sekido Y., Wakai K., Imaizumi K., et al. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharmacogenet Genomics 2005; 15(1)35–41, [INFOTRIEVE], [CSA]
- Kohle C., Mohrle B., Munzel P. A., Schwab M., Wernet D., Badary O. A., et al. Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians. Biochem. Pharmacol 2003; 65(9)1521–1527, [INFOTRIEVE], [CSA], [CROSSREF]
- Koiwai O., Nishizawa M., Hasada K., Aono S., Adachi Y., Mamiya N., et al. Gilbert's syndrome is caused by a heterozygous missense mutation in the gene for bilirubin UDP-glucuronosyltransferase. Hum. Mol. Genet 1995; 4(7)1183–1186, [INFOTRIEVE], [CSA]
- Krishnaswamy S., Hao Q., Al-Rohaimi A., Hesse L. M., von Moltke L. L., Greenblatt D. J., et al. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: I. Identification of polymorphisms in the 5'-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation. J. Pharmacol. Exp. Ther 2005a; 313(3)1331–1339, [INFOTRIEVE], [CSA], [CROSSREF]
- Krishnaswamy S., Hao Q., Al-Rohaimi A., Hesse L. M., von Moltke L. L., Greenblatt D. J., et al. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J. Pharmacol. Exp. Ther 2005b; 313(3)1340–1346, [INFOTRIEVE], [CSA], [CROSSREF]
- Lampe J. W., Bigler J., Horner N. K., Potter J. D. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 1999; 9(3)341–349, [INFOTRIEVE], [CSA]
- Lankisch T. O., Vogel A., Eilermann S., Fiebeler A., Krone B., Barut A., et al. Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene. Mol. Pharmacol 2005; 67(5)1732–1739, [INFOTRIEVE], [CSA], [CROSSREF]
- Ma M. K., McLeod H. L. Lessons learned from the irinotecan metabolic pathway. Curr. Med. Chem 2003; 10(1)41–49, [INFOTRIEVE], [CSA], [CROSSREF]
- Marcuello E., Altes A., Menoyo A., Del Rio E., Gomez-Pardo M., Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 2004; 91(4)678–682, [INFOTRIEVE], [CSA]
- Massacesi C., Terrazzino S., Marcucci F., Rocchi M. B., Lippe P., Bisonni R., et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 2006; 106(5)1007–1016, [INFOTRIEVE], [CSA], [CROSSREF]
- Mathijssen R. H., Marsh S., Karlsson M. O., Xie R., Baker S. D., Verweij J., et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin. Cancer Res 2003; 9(9)3246–3253, [INFOTRIEVE], [CSA]
- Mathijssen R. H., van Alphen R. J., Verweij J., Loos W. J., Nooter K., Stoter G., et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res 2001; 7(8)2182–2194, [INFOTRIEVE], [CSA]
- Nagar S., Remmel R. P. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 2006; 25(11)1659–1672, [INFOTRIEVE], [CSA], [CROSSREF]
- Nagar S., Zalatoris J. J., Blanchard R. L. Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics 2004; 14(8)487–499, [INFOTRIEVE], [CSA], [CROSSREF]
- Narita M., Nagai E., Hagiwara H., Aburada M., Yokoi T., Kamataki T. Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica 1993; 23(1)5–10, [INFOTRIEVE], [CSA]
- Paoluzzi L., Singh A. S., Price D. K., Danesi R., Mathijssen R. H., Verweij J., et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J. Clin. Pharmacol 2004; 44(8)854–860, [INFOTRIEVE], [CSA], [CROSSREF]
- Peters W. H., te Morsche R. H., Roelofs H. M. Combined polymorphisms in UDP-glucuronosyltransferases 1A1 and 1A6: implications for patients with Gilbert's syndrome. J. Hepatol 2003; 38(1)3–8, [INFOTRIEVE], [CSA], [CROSSREF]
- Rouits E., Boisdron-Celle M., Dumont A., Guerin O., Morel A., Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Cancer Res 2004; 10(15)5151–5159, [INFOTRIEVE], [CSA], [CROSSREF]
- Saeki M., Ozawa S., Saito Y., Jinno H., Hamaguchi T., Nokihara H., et al. Three novel single nucleotide polymorphisms in UGT1A10. Drug Metab. Pharmacokinet 2002; 17(5)488–490, [INFOTRIEVE], [CSA], [CROSSREF]
- Saeki M., Saito Y., Jinno H., Sai K., Kaniwa N., Ozawa S., et al. Genetic polymorphisms of UGT1A6 in a Japanese population. Drug Metab. Pharmacokinet 2005; 20(1)85–90, [INFOTRIEVE], [CSA], [CROSSREF]
- Saeki M., Saito Y., Jinno H., Sai K., Komamura K., Ueno K., et al. Three novel single nucleotide polymorphisms in UGT1A9. Drug Metab. Pharmacokinet 2003; 18(2)146–149, [INFOTRIEVE], [CSA], [CROSSREF]
- Sai K., Saeki M., Saito Y., Ozawa S., Katori N., Jinno H., et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther 2004; 75(6)501–515, [INFOTRIEVE], [CSA], [CROSSREF]
- Soepenberg O., Dumez H., Verweij J., de Jong F. A., de Jonge M. J., Thomas J., et al. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. Clin. Cancer Res 2005; 11(4)1504–1511, [INFOTRIEVE], [CSA], [CROSSREF]
- Takasuna K., Hagiwara T., Hirohashi M., Kato M., Nomura M., Nagai E., et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996; 56(16)3752–3757, [INFOTRIEVE], [CSA]
- Takasuna K., Hagiwara T., Hirohashi M., Kato M., Nomura M., Nagai E., et al. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother. Pharmacol 1998; 42(4)280–286, [INFOTRIEVE], [CSA], [CROSSREF]
- Takasuna K., Kasai Y., Kitano Y., Mori K., Kobayashi R., Hagiwara T., et al. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn. J. Cancer Res 1995; 86(10)978–984, [INFOTRIEVE], [CSA]
- Tallman M. N., Ritter J. K., Smith P. C. Differential rates of glucuronidation for 7-ethyl-10-hydroxy-camptothecin (SN-38) lactone and carboxylate in human and rat microsomes and recombinant UDP-glucuronosyltransferase isoforms. Drug Metab. Dispos 2005; 33(7)977–983, [INFOTRIEVE], [CSA], [CROSSREF]
- Tephly T., Green M., Puig J., Irshaid Y. Endogenous substrates for UDP-glucuronosyltransferases. Xenobiotica 1988; 18(11)1201–1210, [INFOTRIEVE], [CSA]
- Tobin P. J., Dodds H. M., Clarke S., Schnitzler M., Rivory L. P. The relative contributions of carboxylesterase and beta-glucuronidase in the formation of SN-38 in human colorectal tumours. Oncol. Rep 2003; 10(6)1977–1979, [INFOTRIEVE], [CSA]
- Tukey R., Strassburg C. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol 2000; 40: 581–616, [INFOTRIEVE], [CSA], [CROSSREF]
- Villeneuve L., Girard H., Fortier L. C., Gagne J. F., Guillemette C. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J. Pharmacol. Exp. Ther 2003; 307(1)117–128, [INFOTRIEVE], [CSA], [CROSSREF]
- Wells P. G., Mackenzie P. I., Chowdhury J. R., Guillemette C., Gregory P. A., Ishii Y., et al. Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab. Dispos 2004; 32(3)281–290, [INFOTRIEVE], [CSA], [CROSSREF]
- Yamanaka H., Nakajima M., Katoh M., Hara Y., Tachibana O., Yamashita J., et al. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 2004; 14(5)329–332, [INFOTRIEVE], [CSA], [CROSSREF]
- Zhou Q., Sparreboom A., Tan E. H., Cheung Y. B., Lee A., Poon D., et al. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br. J. Clin. Pharmacol 2005; 59(4)415–424, [INFOTRIEVE], [CSA], [CROSSREF]